Launch Delays

Place a tracking and data relay satellite in orbit. 

Deploy and retrieve the Spartan satellite, which would have made observations of Halley s comet. 

The crew began training 37 weeks before launch, and the training process was unremarkable. All NASA crew members exceeded the number of training hours required and were certified proficient in all mission tasks. The two pay-load specialists also fulfilled their training requirements. 

The Level I Flight Readiness Review for mission 51-L took place on January 15, 1986. The Flight Readiness Review should address all aspects of flight preparation about which any questions have arisen. In addition, attendees confirm that all equipment and operational plans have been certified by the responsible manager within NASA. Solid rocket booster joints were not discussed during the review on January 15. 

The launch of mission 51-L was postponed three times and scrubbed once from the planned date of January 22, 1986. The first postponement was announced on December 23,1985. That change established the launch date as January 23, 1986, in order to accommodate the final integrated simulation schedule that resulted from the slip in the launch date of mission 61-C. 

---

Danzon, Patricia M., Y. Richard Wang, and Liang Wang. 2005. The Impact of Price Regulation on the Launch Delay of New Drugs Evidence from 25 Markets in the 1990s. Health Economics 14 269-292. 

PL2 Pre Launch Launch delay (due to weather, pre launch test failues, etc.) 1 4 1... 

Adding to the problems is the fact that system safety efforts led to launch delays when problems were found, which created another reason for reducing the priority of the safety efforts in the face of increasing launch pressures. 

Loss of the Shuttle flight opportunity means that the Shuttle is grounded for 6-12 months. Launch delay is a 30-day hold. 

Loss of Shuttle flight opportunity (launch delay)... 

In 1984, the AMPTE mission launched the first carbon-foil TOF-MS into space, which would have been the second, had the Challenger shuttle disaster not delayed the Ulysses launch until 1991 (Fig. 11.2) [23]. The photons were filtered out by a traditional blackened deflection system, which directed the ions toward the 2 p,g/cm2 thick foil mounted on an 85% transparent grid almost a square centimeter in area. The grid provided the support needed to survive the launch. The foil thickness permitted >2keV/nuc ions to pass through and hit a SSD some 10 cm away. To ensure that the ions made it through the foil and also through the dead layer on the SSD (caused by the upper electrode), the foil and the entire TOF section were floated at 20 kV to post-accelerate the ions. Electrons sputtered off the carbon foil became the start, whereas electrons sputtered off the SSD became the stop pulse for the TOF. 

Fabrication of the prototype is an important step in product development. It demonstrates that the various components can indeed be physically integrated to form the final product with the desired functionalities. Consider a UV sensor. While its functionality depends on the physical response of a certain nanomaterial in the presence of UV light, an electric circuit and a display system are required for a functional consumer product. The availability of a prototype is essential in test marketing, safety tests, reliability tests and so on. However, the development of consumer-oriented products often involves a considerable amount of trial-and-error, which can lead to costly delays in product launching [10]. 

Thus, it is highly desirable that key buyers and sales channels have already been locked up by the time of product launch. Inevitably, customers, process engineers, financial officers, and other stakeholders request various design changes. Proper change control is essential to avoid unacceptable delays and cost overruns. 

Roche Diagnostics entered into a 15-yr contract with CombiMatrix in 2001 to supply oligonucleotide arrays for ifs markefs. However, Roche announced a delay in fhe launch of ifs mafriXarray product line. In the... 

We used the cumulative number of drugs with NMEs approved and launched in Taiwan to measure pharmaceutical innovations. The annual number of NMEs introduced into Taiwan between 1985 and 2002 followed cyclic patterns (Fig. 13.1). In 1985, 95 NMEs were introduced in this market. This number decreased to 52 and 49 in the next two years, but increased subsequently. In 1995 only 15 NMEs were introduced, possibly reflecting delays in approvals caused by the transition from the then-existing health care financing system to national health insurance in Taiwan in that year. ... 

From the foregoing discussion, there are clearly many issues to be confronted when scaling up the pan-coating process. Evidently, the more definitive data that are developed initially, the less likely that major problems will occur later on, especially problems that could inevitably delay a product launch and cost much in the way of lost revenues, particularly when dealing with a potentially blockbuster drug product. 

---